Trial Profile
A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in Patients With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Camptothecin (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Sep 2022 Results (n=4) of safety, published in the Oncologist
- 16 Jun 2022 Status changed from completed to discontinued.
- 03 Feb 2022 Status changed from active, no longer recruiting to completed.